The Average Body Surface Area of Adult Cancer Patients in the UK: A Multicentre Retrospective Study by Sacco, Joseph J. et al.
The Average Body Surface Area of Adult Cancer Patients







1Department of Medical Oncology, Clatterbridge Centre for Oncology, Merseyside, United Kingdom, 2Department of Clinical Oncology, Velindre Cancer Centre, Cardiff,
United Kingdom, 3Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, United Kingdom
Abstract
The majority of chemotherapy drugs are dosed based on body surface area (BSA). No standard BSA values for patients being
treated in the United Kingdom are available on which to base dose and cost calculations. We therefore retrospectively
assessed the BSA of patients receiving chemotherapy treatment at three oncology centres in the UK between 1
st January
2005 and 31
st December 2005. A total of 3613 patients receiving chemotherapy for head and neck, ovarian, lung, upper GI/
pancreas, breast or colorectal cancers were included. The overall mean BSA was 1.79 m
2 (95% CI 1.78–1.80) with a mean BSA
for men of 1.91 m
2 (1.90–1.92) and 1.71 m
2 (1.70–1.72) for women. Results were consistent across the three centres. No
significant differences were noted between treatment in the adjuvant or palliative setting in patients with breast or
colorectal cancer. However, statistically significant, albeit small, differences were detected between some tumour groups. In
view of the consistency of results between three geographically distinct UK cancer centres, we believe the results of this
study may be generalised and used in future costings and budgeting for new chemotherapy agents in the UK.
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Introduction
Body surface area (BSA), despite well-documented limita-
tions, remains the most frequently used measure for calculating
the dose of cytotoxic drugs in chemotherapy regimens[1,2]. The
dosing of cytotoxic drugs has been based on the observation that
physiologic variables related to drug metabolism and elimina-
tion, such as basal metabolic rate, renal function and hepatic
function, vary between individuals according to surface area[3].
This type of dosing calculation has traditionally been thought to
reduce the variability in drug exposure between patients.
However more recent research has questioned the reliability
of BSA-based prediction of drug clearance, since the same dose
of drug (per m
2) frequently results in very different pharmaco-
kinetic profiles and toxicity in different patients[4,5]. An
example is the substantial interpatient variability of etoposide
clearance (coefficient of variation of 30%) observed in a study by
Ratain et al[6].
The most widely used formula for BSA calculation is that
devised by Du Bois and Du Bois in 1916. Plaster of Paris moulds of
nine subjects were cut into small pieces in an attempt to measure
the two-dimensional surface area of the skin. Each individual’s
body/skin surface area was then calculated and Du Bois and Du




Notably, this formula was derived from 9 subjects only, one of
whom was a child. The age, sex and nutrition of these subjects,
studied in the middle of the First World War, are unlikely to be
comparable to that of patients receiving chemotherapy in 2009.
However, although several other formulae have since been put
forward[8,9,10], none of these has gained widespread acceptance.
Drug dosage is usually determined by multiplying the patient’s
BSA by a constant that has been derived for each drug in phase 1
and 2 studies. Despite calls for BSA dosing to be replaced with
dosing based on pharmacokinetics or pharmacodynamics, these
new methods are yet to be agreed upon[5,11]. The few exceptions
include carboplatin dosing which is based on creatinine clear-
ance[12] and folinic acid rescue following methotrexate infusion
which is based on serum methotrexate levels.
With the development of new, usually costly chemotherapy and
immunotherapy drugs, the commissioners and providers of cancer
care as well as the National Health Service (NHS) as a whole, need
to estimate how much a particular therapy will on average cost per
year. Such estimates rely in part on an accurate assessment of body
surface area. Although a mean BSA of 1.73 m
2 has been quoted in
previous work [13], this historical value is unlikely to represent
patients currently being treated in the United Kingdom (UK), and
does not take into account gender specific differences or recent
increases in obesity in the general population.
More recent studies performed outside the UK provide some
guidance. An Australian study[2] of 2838 patients receiving
chemotherapy between May 1996 and December 2000 arrived at
an overall mean BSA of 1.80 m
2 (female 1.70 m
2, male 1.89 m
2),
while in an international retrospective audit of 1650 patients on
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8933phase I trials between 1991 and 2001, Baker et al [14] reported a
BSA of 1.86 m
2. Notably, the latter study potentially represents a
fitter group of patients with a higher BSA than the general
population.
The lack of a standard BSA value on which to base these dose
and cost calculations is reflected in the varying values used by the
National Institute for Health and Clinical Excellence (NICE) in
the appraisal of new agents. For instance, in recent guidance on
the administration of cetuximab and bevacizumab to patients
with metastatic colorectal cancer a mean BSA of 1.75 m
2 was
used[15]. However, the evidence review group for the use of
cetuximab for patients with squamous cell carcinomas of the head
and neck[16] used an average BSA of 1.7 m
2. In an appraisal of
pemetrexed for the second line treatment of non-small cell lung
cancer, the manufacturers assumed a mean BSA of 1.7 m
2 while
the evidence review group used a BSA of 1.83 m
2[17]. Although
these values appear quite similar, small differences can be of great
significance as they may have an effect on the part use of an
additional vial of chemotherapy leading to potential waste and
therefore increased cost.
Dose banding, whereby prescribed chemotherapy doses are
rounded up or down to pre-determined standard doses, is a
common practice including in the three centres studied. In some
malignancies, this reduces waste, treatment delays and minimises
errors in making up unusual volumes of chemotherapy
agent[2,18]. Dose banding is almost invariably performed within
a 5% tolerance limit and therefore does not result in a significant
change to the administered dose.
This study was designed to establish the mean BSA of patients
receiving chemotherapy in the UK and whether there are
statistically significant differences in the BSA values for:
N patients in different parts of the country
N men and women
N patients with different tumour types
N patients receiving adjuvant chemotherapy and those receiving
palliative or second line treatment.
With this information, more accurate estimates can be made of
the average dose of an agent and the likely consequent cost to a
service of expensive drugs.
Methods
Ethics Statement
The study did not require patient consent or approval by an
ethics committee, as no intervention was involved, data were
anonymised and no patient identifying information was included.
A retrospective study was performed assessing patients receiving
chemotherapy treatment in three cancer centres in different areas
of England and Wales–the Clatterbridge Centre for Oncology in
Merseyside, Velindre Cancer Centre in Cardiff and the Dorset
Cancer Centre in Poole.
In each of these centres, data were collected on patients who
started a chemotherapy regimen between 1
st January 2005 and
31
st December 2005. Patients receiving chemotherapy for the
following cancers were included: head and neck, ovarian, lung,
upper GI/pancreas, breast and colorectal. All intravenous and
oral chemotherapy regimens were included except single agent
carboplatin because the dose calculation for this drug is
independent of BSA. Immunotherapies, intrathecal and intrapleu-
ral chemotherapies were also excluded. No minimum age was
applied.
In Poole and Cardiff, where records of all chemotherapy
prescriptions are kept electronically, it was possible to obtain all
the relevant data by exporting patients’ details from computerised
chemotherapy programmes (Clinichemo and ChemoCare). A
proportion of the lung cancer patients in Cardiff received their
chemotherapy at Llandough Hospital and data about height,
weight and BSA were obtained from the local tumour-specific
database.
In Clatterbridge, chemotherapy prescriptions are not recorded
electronically and so only demographic data could be obtained
electronically from the MAXIMS database. Height, weight and
BSA were obtained from the original chemotherapy scripts, which
are filed with the patients’ clinical records.
Figure 1. Patient identification and inclusion in study. Only cases in which a full dataset could be obtained were included in the study. This
was possible for over 80% of patients in all 3 centres, with only a relatively small number excluded, mainly due to misfiling or loss of chemotherapy
scripts.
doi:10.1371/journal.pone.0008933.g001
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The BSA on their chemotherapy prescription was also noted. If a
patient started more than one chemotherapy regimen during the
12 month period, the data were collected for each regimen
because their weight and hence BSA might have changed.
Treatment intent (i.e. neo/adjuvant or palliative) was also
recorded for all patients with breast or colorectal cancer. Only a
small percentage of patients received neoadjuvant chemotherapy,
and these cases were included in the adjuvant group for analysis.
The above data were entered into Excel spreadsheets. We
recalculated the BSA for each patient using the Dubois and




0.007184) and this value was used for further calculations. This
was done to verify the accuracy of the original calculation and to
remove any dose capping.
Statistical analyses were performed using SPSS version 15. All
significance testing employed an independent sample Student’s t-
test, and was 2- tailed.
Results
A total of 4318 patients were identified as meeting the eligibility
criteria. A full data set was obtained for 3613 patients (84%), and
over 80% of patients from each centre were included (figure 1).
The remaining patients were excluded because a complete data set
was not available due to inaccurate filing and missing or
unavailable records. Table 1 illustrates the demographic data for
patients included in the study.
The overall mean BSA for the patient population was 1.79 m
2
(95% CI 1.78, 1.80). For both sexes, the BSA distribution was
approximately normal as shown in figure 2. The mean BSA for
men was 1.91 m
2 (1.90, 1.91) compared to1.71 m
2 (1.70, 1.72) for
women, with a median of 1.90 and 1.70 respectively. Previous
studies have employed the mean in preference to the median, a
convention we have continued as the distribution approximated
normal, and the mean better incorporates outliers which may have
significant effects on costing.
The difference in mean BSA between male and female patients
was statistically significant (p,0.0005), and apparent in all sub-
groups, as shown in Table 2. In both sexes, there was a weak
negative correlation between BSA and age as shown in figure 3. A
breakdown of BSA data for each tumour site at each oncology
centre is shown in Table 3. In each tumour site, the mean BSA is
consistent across the three centres with overlapping confidence
intervals.
A comparison was made between the BSA for patients receiving
neoadjuvant or adjuvant chemotherapy and those receiving
treatment in the palliative setting for breast and colorectal
carcinoma. In both instances there were no statistically significant
differences (p=0.323 and p=0.152 respectively).
On the other hand, differences between tumour sites are
apparent. The mean BSA for women with breast cancer was
significantly higher than those for women with colorectal, head
and neck, lung, upper GI and ovarian cancer (p,0.0005, 0.001,
,0.0005, ,0.0005 and 0.002 respectively). However, no statisti-
cally significant differences were observed among the latter five
groups.
In men, a higher mean BSA was observed in those with
colorectal cancer compared to those with upper GI, lung or head
and neck cancer (p=0.019, 0.002 and ,0.0005 respectively). Men
with head and neck cancer also had a significantly lower BSA than
those with either lung or upper GI cancer (p=0.026 and 0.010
respectively).
Discussion
Recent media coverage continues to highlight the problems of
introducing new, costly cancer chemotherapy agents into the
NHS. Regulatory bodies in several countries, including the UK,
routinely consider evidence of cost-effectiveness when deciding on
reimbursement of new therapeutic agents. Evaluation of cost
effectiveness as carried out by the NICE technology appraisal
process[19] requires estimating the drug costs for the average
patient, which for most chemotherapy drugs involves calculations
based on expected BSA values.
The importance of using accurate data and appropriate
calculation methods can be illustrated from experience in the
UK, where NICE considered the merits of pemetrexed[17] and
erlotinib[20] compared to docetaxel for the treatment of non-small
Table 1.
Velindre Clatterbridge Dorset Combined
Number eligible 1310 2405 603 4318
Included (%) 1077 (82) 2035 (85) 501 (83) 3613 (84)
Median Age 61 60 65 61
Male (%) 427 (39.6) 843 (41.4) 201 (40.1) 1471 (40.7)
Female (%) 650 (60.4) 1192 (58.6) 300 (59.9) 2142 (59.3)
doi:10.1371/journal.pone.0008933.t001
Figure 2. Histograms depicting the distribution of body surface area in men and women undergoing chemotherapy. As illustrated,
the distribution approximates normal in both sexes.
doi:10.1371/journal.pone.0008933.g002
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doses of docetaxel could be calculated on the basis of a mean BSA
of 1.7 m
2 for all patients (male and female). The costs of
pemetrexed were calculated on a similar basis (erlotinib in tablet
form does not require dose adjustment according to BSA). On this
basis, it appeared that the extra cost of switching to pemetrexed is
£3,006 per patient and for erlotinib is £1,865 per patient.
However, the calculations employed a relatively low mean BSA,
and did not take into consideration the effects of the distibution of
BSA values in the population. The latter may have a significant
effect on the final estimate of incremental cost, due mainly to
effects on vial usage. Chemotherapy agents are frequently
marketed in large vial sizes, leading to a stepwise rather than
continuous increase in vials (and hence cost) with increasing BSA.
Although vial sharing may help prevent wastage, this is only
possible in relatively large centres for more common tumour types,
and may be affected by the stability of the agent.
Using the BSA results for lung cancer patients in Table 2, and
assuming 70% of such patients are male, the combined population
mean BSA would be 1.818. A recalculation using this mean BSA
and taking into consideration the distribution of BSA values is
shown in Appendix S1. Incremental drug costs per patient would
be £3,712 (23% more than originally proposed) for pemetrexed
and £1,840 (1% less) for erlotinib. Differences of this order are
likely to have important consequences for pharmacy budgets, and
may be decisive in reimbursement decisions. Further discussion
and examples of the utility of the data provided by this study are
provided in Appendix S2, based on several NICE technology
appraisals.
In the absence of reliable estimates of BSA distribution in UK
adult patients with cancer, cost-effectiveness evaluations have
previously depended on the use of data derived from studies
conducted in other countries (table 4). In this study, we provide an
estimate for the overall mean BSA for patients receiving
chemotherapy at three centres in England and Wales. Addition-
ally, we have analysed the BSA by geographical area, sex and
tumour site. The results were consistent between the three
geographical areas (North West England, South England and
South Wales), and we therefore believe that these values can be
extrapolated across the whole of the UK population.
Unsurprisingly BSA varied with both sex and age. Men had a
significantly higher BSA value than women (p,0.0005) and for
both men and women the BSA declined with age (fig. 2). However
the association between age and BSA was relatively weak (Pearson
correlation coefficient of 20.124 and 20.157 for men and women
respectively). Notably, the Dorset patients were older on average
than those of the other two centres, but this was not reflected in
significantly lower BSA values.
This study was designed to allow calculation of the mean BSA
for patients with different tumour types. The tumour sites selected
reflect those patients commonly treated with chemotherapy (such
as breast cancer). On the other hand prostate cancer, which is
primarily treated with hormone therapy was not included. This is
reflected in the higher proportion of female patients in this study,
as breast cancer and prostate cancer are the most common cancers
in men and women respectively. We specifically concentrated on
larger groups to eliminate the bias from small numbers of patients
treated with chemotherapy for other tumour sites. We feel that
most of the tumour site groups are large enough to allow
generalisation of results although we acknowledge that we had
data on comparatively few (155) head and neck cancer patients.
Because of this criterion, we have included two tumour sites, breast
Table 2.
Male Female
Adjuvant Breast n 4 685
Mean (CI) 2.10 (1.59,2.61) 1.75(1.74,1.77)
Palliative Breast n 4 282
Mean (CI) 2.06 (1.85,2.28) 1.74 (1.72,1.76)
Adjuvant Colon n 335 210
Mean (CI) 1.92 (1.90,1.94) 1.68 (1.65,1.70)
Palliative Colon n 291 151
Mean (CI) 1.93 (1.91,1.96) 1.68 (1.65,1.71)
Head and Neck n 117 38
Mean (CI) 1.85 (1.81,1.88) 1.65 (1.59,1.72)
Lung n 390 331
Mean (CI) 1.89 (1.87,1.91) 1.65 (1.64,1.67)
Ovarian n 0 321
Mean (CI) - 1.71 (1.69,1.73)
Upper GI n 330 124
Mean (CI) 1.90 (1.88,1.92) 1.65 (1.62,1.69)
Combined n 1471 2142
Mean (CI) 1.91 (1.90, 1.91) 1.71 (1.70, 1.72)
doi:10.1371/journal.pone.0008933.t002
Figure 3. Correlation between age and BSA. The BSA was negatively correlated with age in both genders as shown in the scatterplots above.
The Pearson correlation coefficient was 20.124 and 20.157 respectively and both results were statistically significant (p,0.0005).
doi:10.1371/journal.pone.0008933.g003
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accounts for the higher proportion of female patients in this study.
It is commonly assumed that patients receiving palliative
chemotherapy have a lower BSA than those receiving treatment
in the neoadjuvant or adjuvant setting, because the more
advanced tumours might be associated with significant anorexia
and weight loss. We analysed data from two tumour sites (breast
and colorectal carcinoma) to investigate this hypothesis. In both
cases, there was no statistically significant difference between the
mean BSA results, even though palliative chemotherapy included
second and third line regimens. This might be due to stringent
patient selection for palliative chemotherapy making it less likely
that patients with significant weight loss received chemotherapy.
However, small but statistically significant differences were
observed between some tumour groups. In particular, women with
ovarian cancer had a significantly lower BSA than those with
breast cancer and patients with lung cancer had a significantly
lower BSA than those with colon cancer. In both cases this is
presumably related to the well known association of both ovarian
and lung cancer with significant weight loss and anorexia.
A maximum BSA of 2 m
2 is commonly used for dose
calculations in obese patients. This capping is based in part on
small trials which indicate reduced clearance of some chemother-
apy agents in obese patients[21,22]. However the results of a
recent pharmacokinetic study suggest that, for most evaluated
drugs, full BSA should be used for dose calculation[23].
Additionally, recent studies in breast cancer have indicated dose
capping may result in underdosing of some patients[24,25]. For
this reason we have not incorporated dose capping in our BSA
calculations. However we have appended the raw BSA data for
each tumour group (Appendix S3), thus allowing recalculation of
BSA, taking capping into account. Notably dose capping at a BSA
of 2 may have significant cost implications, as patients dosed on
the basis of a BSA exceeding 2 would require a further vial. In our
study 28% of male patients and 6.6% of female patients had a BSA
over 2.00, and would potentially fall into this bracket. Assuming
dose banding with 5% tolerance the proportion would be reduced
to 14.5% for men and 2.4% for women.
This study provides a reliable estimate for the mean BSA of men
and women receiving chemotherapy in the UK (1.91 and 1.71
respectively). While a tumour specific estimate may be more
accurate for some tumour types, these differences were relatively
small. This information will not only be of value to those
calculating the future cost impact of new chemotherapy agents for
which the dose is calculated from the BSA, but also to those
estimating the cost-effectiveness of new and established agents.
Supporting Information
Appendix S1
Found at: doi:10.1371/journal.pone.0008933.s001 (0.05 MB
XLS)
Appendix S2
Found at: doi:10.1371/journal.pone.0008933.s002 (0.03 MB
DOC)
Appendix S3 Body surface area raw data.
Found at: doi:10.1371/journal.pone.0008933.s003 (0.58 MB
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Table 3.
Velindre Clatterbridge Dorset Combined
Adjuvant Breast n 207 430 52 689
Mean (CI) 1.76 (1.73,1.78) 1.76 (1.74,1.78) 1.74 (1.69,1.78) 1.76 (1.74,1.77)
Palliative Breast n 80 170 36 286
Mean (CI) 1.74 (1.69,1.78) 1.75 (1.72,1.77) 1.73 (1.67,1.79) 1.74 (1.72,1.76
Adjuvant Colon n 158 308 79 545
Mean (CI) 1.81 (1.78,1.84) 1.84 (1.81,1.86) 1.81 (1.76,1.86) 1.83 (1.81,1.84)
Palliative Colon n 186 214 42 442
Mean (CI) 1.83 (1.80,1.86) 1.86 (1.82,1.89) 1.86 (1.80,1.92) 1.85 (1.83,1.87)
H & N n 43 67 45 155
Mean (CI) 1.75 (1.68,1.82) 1.83 (1.78,1.88) 1.80 (1.75,1.86) 1.80 (1.77,1.83)
Lung n 154 486 81 721
Mean (CI) 1.77 (1.73,1.80) 1.78 (1.76,1.80) 1.84 (1.80,1.88) 1.78 (1.77,1.80)
Ovarian n 107 114 100 321
Mean (CI) 1.72 (1.69,1.75) 1.71 (1.68,1.75) 1.71 (1.67,1.75) 1.71 (1.69,1.73)
Upper GI n 142 246 66 454
Mean (CI) 1.81 (1.78,1.84) 1.84 (1.82,1.87) 1.84 (1.78,1.88) 1.83 (1.81,1.85)
Combined n 1077 2035 501 3613
Mean (CI) 1.78 (1.77–1.79) 1.79 (1.79,1.80) 1.79 (1.77,1.81) 1.79 (1.78,1.80)
doi:10.1371/journal.pone.0008933.t003
Table 4.
Area Average Body Surface area
USA 1.86 m2 (Baker et al)
Not reported 1.73 m2 (Ratain)
Australia 1.80 m2 (Dooley et al)
UK 1.79 m2 (Sacco et al)
doi:10.1371/journal.pone.0008933.t004
BSA in UK Cancer Patients
PLoS ONE | www.plosone.org 5 January 2010 | Volume 5 | Issue 1 | e8933Acknowledgments
We would like to thank Sian Evans and Lyn Jackson, Chief Pharmacists at
Velindre Cancer Centre and Dorset Cancer Centre respectively for their
involvement in case identification and data collection. Particular thanks
also to Dr Helen Wong (Statistician and Clinical Effectiveness Co-
ordinator, Clatterbridge Centre for Oncology) for her invaluable
assistance.
Author Contributions
Conceived and designed the experiments: JJS JB FM PC. Performed the
experiments: JJS JB. Analyzed the data: JJS JB FM AB PC. Contributed
reagents/materials/analysis tools: AB. Wrote the paper: JJS JB FM AB PC.
References
1. Kaestner SA, Sewell GJ (2007) Chemotherapy dosing part I: scientific basis for
current practice and use of body surface area. Clin Oncol (R Coll Radiol) 19:
23–37.
2. Dooley MJ, Singh S, Michael M (2004) Implications of dose rounding of
chemotherapy to the nearest vial size. Support Care Cancer 12: 653–656.
3. Sawyer M, Ratain MJ (2001) Body surface area as a determinant of
pharmacokinetics and drug dosing. Invest New Drugs 19: 171–177.
4. Undevia SD, Gomez-Abuin G, Ratain MJ (2005) Pharmacokinetic variability of
anticancer agents. Nat Rev Cancer 5: 447–458.
5. Gurney H (1996) Dose calculation of anticancer drugs: a review of the current
practice and introduction of an alternative. J Clin Oncol 14: 2590–2611.
6. Ratain MJ, Mick R, Schilsky RL, Vogelzang NJ, Berezin F (1991)
Pharmacologically based dosing of etoposide: a means of safely increasing dose
intensity. J Clin Oncol 9: 1480–1486.
7. DuBois D, DuBois EF (1916) A formula to estimate the approximate surface
area if height and weight be known. Arch Internal Med 17: 863–871.
8. Mosteller RD (1987) Simplified calculation of body-surface area. N Engl J Med
317: 1098.
9. Gehan EA, George SL (1970) Estimation of human body surface area from
height and weight. Cancer Chemother Rep 54: 225–235.
10. Boyd E (1935) The growth of the surface area of the human body. Minneapolis:
University of Minnesota press.
11. Felici A, Verweij J, Sparreboom A (2002) Dosing strategies for anticancer drugs:
the good, the bad and body-surface area. Eur J Cancer 38: 1677–1684.
12. Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, et al. (1989)
Carboplatin dosage: prospective evaluation of a simple formula based on renal
function. J Clin Oncol 7: 1748–1756.
13. Ratain MJ (1998) Body-surface area as a basis for dosing of anticancer agents:
science, myth, or habit? J Clin Oncol 16: 2297–2298.
14. Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, et al. (2002)
Role of body surface area in dosing of investigational anticancer agents in adults,
1991–2001. J Natl Cancer Inst 94: 1883–1888.
15. Ashcroft D, Barnett D, Barry P, Buckley B, Cairns J, et al. (2007) NICE
technology appraisal guidance 118: Bevacizumab and cetuximab for the
treatment of metastatic colorectal cancer. Available: http://www.nice.org.uk/
nicemedia/pdf/TA118Guidance.pdf. Accessed 2009 April 6.
16. Barnett D, Black DW, Buckley B, Campbell C, Clark P, et al. (2007) Head and
neck cancer - cetuximab: appraisal consultation document. Available: http://
www.nice.org.uk/guidance/index.jsp?action=article&r=true&o=34962. Ac-
cessed: 2009 April 6.
17. Bagust A, Boland A, Dundar Y, Davis H, Dickson R, et al. (2006) Pemetrexed
for the treatment of relapsed non-small cell lung cancer: Evidence Review
Group report. Available: http://www.nice.org.uk/nicemedia/pdf/Lungcancer_
pemetrexed_ERG.pdf. Accessed: 2009 April 6.
18. MacLean F, Macintyre J, McDade J, Moyes D (2003) Dose banding of
chemotherapy in the Edinburgh Cancer Centre. Pharm J 2003: 691–693.
19. Littlejohns P, Barnett D, Longson C (2003) The cancer technology appraisal
programme of the UK’s National Institute for Clinical Excellence. Lancet Oncol
4: 242–250.
20. Bagust A, Boland A, Dundar Y, Davis H, Dickson R, et al. (2006) Erlotinib
for the treatment of relapsed non-small cell lung cancer: Evidence Review
Group report. Available: http://www.nice.org.uk/nicemedia/pdf/Lungcancer_
erlotinib_ERGreport.pdf. Accessed: 2009 April 6.
21. Powis G, Reece P, Ahmann DL, Ingle JN (1987) Effect of body weight on the
pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer
Chemother Pharmacol 20: 219–222.
22. Rodvold KA, Rushing DA, Tewksbury DA (1988) Doxorubicin clearance in the
obese. J Clin Oncol 6: 1321–1327.
23. Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, et al.
(2007) Evaluation of alternate size descriptors for dose calculation of anticancer
drugs in the obese. J Clin Oncol 25: 4707–4713.
24. Rosner GL, Hargis JB, Hollis DR, Budman DR, Weiss RB, et al. (1996)
Relationship between toxicity and obesity in women receiving adjuvant
chemotherapy for breast cancer: results from cancer and leukemia group B
study 8541. J Clin Oncol 14: 3000–3008.
25. Colleoni M, Li S, Gelber RD, Price KN, Coates AS, et al. (2005) Relation
between chemotherapy dose, oestrogen receptor expression, and body-mass
index. Lancet 366: 1108–1110.
BSA in UK Cancer Patients
PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e8933